De CDC-functionarissen die de definitie van de ziekte van Lyme wijzigden, bezitten patenten op vaccins en test kits. Barbara Johnson, die de Dearborn bijeenkomst in 1994 leidde, bezit vijf patenten met SmithKline, de fabrikant van LYMERix.
Eén van haar patenten uit 1992-1993 toont aan dat er twee verschillende uitkomsten van OspA zijn: de ene is de genetische HLA-gekoppelde overgevoeligheid of allergische, Lyme artritis reactie (15%) en de andere is de neurologische immuunsuppressieve Lyme of B-cel-aids (85%).
“Summary of the Invention
“In one aspect, the invention provides isolated B. burgdorferi antigens which are regulated and differentiated by growth of the B. burgdorferi in a tick vector. Novel antigens of the invention are listed below in Table I.”
“Certain of these antigens are characterized as being B. burgdorferi B31 strain specific and major histocompatibility complex (MHC) nonrestricted. Certain other of these antigens are characterized as being MHC-restricted.”
Meer lezen: Charge Sheet 2: The Patents
Overwin Lyme 